Tags

Type your tag names separated by a space and hit enter

Adrenocorticotropic Hormone (and Challenge Tests)

Synonym/Acronym:
Corticotropin, ACTH.

Rationale
To assist in the investigation of adrenocortical dysfunction using ACTH and cortisol levels in diagnosing disorders such as Addison disease, Cushing disease, and Cushing syndrome.

Patient Preparation
There are no food or fluid restrictions unless by medical direction. Drugs that enhance steroid metabolism may be withheld by medical direction before metyrapone stimulation testing. Instruct the patient to refrain from smoking, avoid alcohol use, avoid strenuous exercise for 12 hr before the test, and remain in bed or at rest for 1 hr immediately before the test. Samples should be collected at the same time of day, between 0600 and 0800.

ProcedureIndicationsMedication Administered, Adult DosageRecommended Collection Times
ACTH stimulation, rapid testSuspect adrenal insufficiency (Addison disease) or congenital adrenal hyperplasia1 mcg (low-dose physiological protocol) cosyntropin intramuscular (IM) or IV; 250 mcg (standard pharmacological protocol) cosyntropin IM or IVThree cortisol levels: Baseline immediately before bolus, 30 min after bolus, and 60 min (optional) after bolus. Baseline and 30-min levels are adequate for accurate diagnosis using either dosage; low-dose protocol sensitivity is most accurate for 30-min level only.
Corticotropin-releasing hormone (CRH) stimulationDifferential diagnosis between ACTH-dependent conditions such as Cushing disease (pituitary source) or Cushing syndrome (ectopic source) and ACTH-independent conditions such as Cushing syndrome (adrenal source)IV dose of 1 mcg/kg human CRHEight cortisol and eight ACTH levels: Baseline collected 15 min before injection, 0 min before injection, and then 5, 15, 30, 60, 120, and 180 min after injection
Dexamethasone suppression (overnight)Differential diagnosis between ACTH-dependent conditions such as Cushing disease (pituitary source) or Cushing syndrome (ectopic source) and ACTH-independent conditions such as Cushing syndrome (adrenal source)Oral dose of 1 mg dexamethasone (Decadron) at 2300Cortisol level at 0800 on the morning after the dexamethasone dose
Metyrapone stimulation (overnight)Suspect hypothalamic/pituitary disease such as adrenal insufficiency, ACTH-dependent conditions such as Cushing disease (pituitary source) or Cushing syndrome (ectopic source), and ACTH-independent conditions such as Cushing syndrome (adrenal source)Oral dose of 30 mg/kg metyrapone with snack at 2400Cortisol, 11-deoxycortisol, and ACTH at 0800 on the morning after the metyrapone dose

Normal Findings
Method: Immunochemiluminescent assay for ACTH and cortisol; high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS) for 11-deoxycortisol.

ACTH

AgeConventional UnitsSI Units (Conventional Units × 0.22)
Cord blood50–570 pg/mL11–125 pmol/L
Newborn10–185 pg/mL2–41 pmol/L
1 wk–9 yr5–46 pg/mL1.1–10.1 pmol/L
10–18 yr6–55 pg/mL1.3–12.1 pmol/L
19 yr–Adult
Male supine (specimen collected in morning)7–69 pg/mL1.5–15.2 pmol/L
Female supine (specimen collected in morning)6–58 pg/mL1.3–12.8 pmol/L
Values may be unchanged or slightly elevated in healthy older adults. Long-term use of corticosteroids, to treat arthritis and autoimmune diseases, may suppress secretion of ACTH.

ACTH Challenge Tests

ACTH (Cosyntropin) Stimulated, Rapid TestConventional UnitsSI Units (Conventional Units × 27.6)
BaselineCortisol greater than 5 mcg/dLGreater than 138 nmol/L
30- or 60-min responseCortisol 18–20 mcg/dL or incremental increase of 7 mcg/dL over baseline value497–552 nmol/L or incremental increase of 193.2 nmol/L over baseline value
Corticotropin-Releasing Hormone StimulatedConventional UnitsSI Units (Conventional Units × 27.6)
Cortisol peaks at greater than 20 mcg/dL within 30–60 minGreater than 552 nmol/L
SI Units (Conventional Units × 0.22)
ACTH increases twofold to fourfold within 30–60 minTwofold to fourfold increase within 30–60 min
Dexamethasone Suppressed Overnight TestConventional UnitsSI Units (Conventional Units × 27.6)
Cortisol less than 1.8 mcg/dL next dayLess than 49.7 nmol/L
Metyrapone Stimulated Overnight TestConventional UnitsSI Units (Conventional Units × 27.6)
Cortisol less than 3 mcg/dL next dayLess than 83 nmol/L
SI Units (Conventional Units × 0.22)
ACTH greater than 75 pg/mLGreater than 16.5 pmol/L
SI Units (Conventional Units × 28.9)
11-deoxycortisol greater than 7 mcg/dLGreater than 202 nmol/L

Critical Findings and Potential Interventions
N/A

Overview

(Study type: Blood collected in a prechilled lavender-top [EDTA] tube for ACTH and from a prechilled red-top tube for cortisol and 11-deoxycortisol; related body system: Endocrine system.) Gold-, tiger-, and green-top (heparin) tubes are also acceptable for cortisol, but care must be taken to use the same type of collection container for serial measurements. Alternatively, specimens can be collected in a prechilled heparinized plastic syringe and carefully transferred into the appropriate tube types by gentle injection to avoid hemolysis. Immediately transport specimen, tightly capped and in an ice slurry, to the laboratory. Hypothalamic-releasing factor stimulates the release of ACTH from the anterior pituitary gland. ACTH stimulates adrenal cortex secretion of glucocorticoids, androgens, and, to a lesser degree, mineralocorticoids. Cortisol is the major glucocorticoid secreted by the adrenal cortex. ACTH and cortisol test results are evaluated together because a change in one normally causes a change in the other. ACTH secretion is stimulated by insulin, metyrapone, and vasopressin. It is decreased by dexamethasone. Cortisol excess from any source is termed Cushing syndrome. Cortisol excess resulting from ACTH excess produced by the pituitary is termed Cushing disease. ACTH levels exhibit a diurnal variation, peaking between 0600 and 0800 and reaching the lowest point between 1800 and 2300. Evening levels are generally one-half to two-thirds lower than morning levels. Cortisol levels also vary diurnally, with the peak values occurring between 0600 and 0800 and reaching the lowest levels between 2000 and 2400. Specimens are typically collected at 0800 and 1600. This pattern may be reversed in individuals who sleep during daytime hours and are active during nighttime hours. Salivary cortisol levels are known to parallel blood levels and can be used to screen for Cushing disease and Cushing syndrome.

Indications

  • Determine adequacy of replacement therapy in congenital adrenal hyperplasia.
  • Determine adrenocortical dysfunction.
  • Differentiate between increased ACTH release with decreased cortisol levels and decreased ACTH release with increased cortisol levels.

Interfering Factors

Contraindications

The metyrapone stimulation test is contraindicated in patients with suspected adrenal insufficiency because it may induce an acute adrenal crisis, a life-threatening condition, in patients whose adrenal function is already compromised.

Factors that may alter the results of the study

  • Drugs and other substances that may increase ACTH levels include insulin, metoclopramide, metyrapone, mifepristone (RU 486), spironolactone, and vasopressin.
  • Drugs and other substances that may decrease ACTH levels include corticosteroids (e.g., dexamethasone) and pravastatin.
  • Excessive physical activity can produce elevated levels.
  • Test results are affected by the time the test is done because ACTH levels vary diurnally, with the highest values occurring between 0600 and 0800 and the lowest values occurring at night.

Rapid clearance of metyrapone, resulting in falsely increased cortisol levels, may occur if the patient is taking drugs that enhance steroid metabolism (e.g., phenytoin, rifampin, phenobarbital, mitotane, and corticosteroids). The requesting health-care provider (HCP) should be consulted prior to a metyrapone stimulation test regarding a decision to withhold these medications.

Other Considerations:

Metyrapone may cause gastrointestinal distress and/or confusion. Administer oral dose of metyrapone with milk and snack.

Potential Medical Diagnosis: Clinical Significance of Results

ACTH Result

Because ACTH and cortisol secretion exhibit diurnal variation with values being highest in the morning, a lack of change in values from morning to evening is clinically significant. Decreased concentrations of hormones secreted by the pituitary gland and its target organs are observed in hypopituitarism. In primary adrenal insufficiency (Addison disease), because of adrenal gland destruction by tumor, infectious process, or immune reaction, ACTH levels are elevated, while cortisol levels are decreased. Both ACTH and cortisol levels are decreased in secondary adrenal insufficiency (i.e., secondary to pituitary insufficiency). Excess ACTH can be produced ectopically by various lung cancers such as oat-cell cancer and large-cell cancer of the lung and by benign bronchial carcinoid tumor.

Challenge Tests and Results

The ACTH (cosyntropin) stimulated rapid test directly evaluates adrenal gland function and indirectly evaluates pituitary gland and hypothalamus function. Cosyntropin is a synthetic form of ACTH. A baseline cortisol level is collected before the injection of cosyntropin. Specimens are subsequently collected at 30- and 60-min intervals. If the adrenal glands function normally, cortisol levels rise significantly after administration of cosyntropin.

The CRH stimulation test works as well as the dexamethasone suppression test (DST) in distinguishing Cushing disease from conditions in which ACTH is secreted ectopically (e.g., tumors not located in the pituitary gland that secrete ACTH). Patients with pituitary tumors tend to respond to CRH stimulation, whereas those with ectopic tumors do not. Patients with adrenal insufficiency demonstrate one of three patterns depending on the underlying cause:

  • Primary adrenal insufficiency—high baseline ACTH (in response to IV-administered ACTH) and low cortisol levels pre- and post-IV ACTH.
  • Secondary adrenal insufficiency (pituitary)—low baseline ACTH that does not respond to ACTH stimulation. Cortisol levels do not increase after stimulation.
  • Tertiary adrenal insufficiency (hypothalamic)—low baseline ACTH with an exaggerated and prolonged response to stimulation. Cortisol levels usually do not reach 20 mcg/dL (SI = 552 nmol/L).

(The DST is useful in differentiating the causes of increased cortisol levels. Dexamethasone is a synthetic glucocorticoid that is significantly more potent than cortisol. It works by negative feedback. It suppresses the release of ACTH in patients with a normal hypothalamus. A cortisol level less than 1.8 mcg/dL [SI = 49.7 nmol/L] usually excludes Cushing syndrome. With the DST, a baseline morning cortisol level is collected, and the patient is given a 1-mg dose of dexamethasone at bedtime. A second specimen is collected the following morning. If cortisol levels have not been suppressed, adrenal adenoma is suspected. The DST also produces abnormal results in the presence of certain psychiatric illnesses [e.g., endogenous depression]).

The metyrapone stimulation test is used to distinguish corticotropin-dependent causes (pituitary Cushing disease and ectopic Cushing disease) from corticotropin-independent causes (e.g., cancer of the lung or thyroid) of increased cortisol levels. Metyrapone inhibits the conversion of 11-deoxycortisol to cortisol. Cortisol levels should decrease to less than 3 mcg/dL if normal pituitary stimulation by ACTH occurs after an oral dose of metyrapone. Specimen collection and administration of the medication are performed as with the overnight dexamethasone test.

Increased In:

Overproduction of ACTH can occur as a direct result of either disease (e.g., primary or ectopic tumor that secretes ACTH) or stimulation by physical or emotional stress, or it can be an indirect response to abnormalities in the complex feedback mechanisms involving the pituitary gland, hypothalamus, or adrenal glands.

ACTH Increased in

  • Addison disease (primary adrenocortical hypofunction)
  • Carcinoid syndrome
  • Congenital adrenal hyperplasia
  • Cushing disease (pituitary-dependent adrenal hyperplasia)
  • Cushing syndrome (ectopic secretion of ACTH)
  • Depression
  • Ectopic ACTH-producing tumors
  • Menstruation
  • Nelson syndrome (ACTH-producing pituitary tumors)
  • Pregnancy
  • Sepsis
  • Septic shock
  • Type 2 diabetes

Decreased In:

Secondary adrenal insufficiency due to hypopituitarism (inadequate production by the pituitary) can result in decreased levels of ACTH. Conditions that result in overproduction or availability of high levels of cortisol can also result in decreased levels of ACTH.

ACTH Decreased in

  • Adrenal adenoma
  • Adrenal cancer
  • Cushing syndrome
  • Exogenous steroid therapy

Summary of the Relationship Between Cortisol and ACTH Levels in Conditions Affecting the Adrenal and Pituitary Glands
DiseaseCortisol LevelACTH Level
Addison disease (adrenal insufficiency)DecreasedIncreased
Cushing disease (pituitary adenoma)IncreasedIncreased
Cushing syndrome related to ectopic source of ACTHIncreasedIncreased
Cushing syndrome (ACTH independent; adrenal cancer or adenoma)IncreasedDecreased
Congenital adrenal hyperplasiaDecreasedIncreased

Nursing Implications

Potential Nursing Problems Assessment and Nursing Diagnosis

ProblemsSigns and Symptoms
Fluid volume (water) (related to retention of sodium and water secondary to cortisol excess)Weight gain, hypertension, tachycardia, edema, jugular vein distention, shortness of breath, abnormal blood gas results
Infection risk (related to impaired immune response secondary to elevated cortisol level, collagen tissue loss, catabolism of peripheral tissues)Delayed wound healing, inhibited collagen formation, impaired blood flow to edematous tissues, symptoms of infection (temperature, increased heart rate, increased blood pressure, shaking, chills, mottled skin, lethargy, fatigue, swelling, edema, pain, localized pressure, diaphoresis, night sweats, confusion, vomiting, nausea, headache)
Injury risk (related to poor wound healing, decreased bone density, capillary fragility)Easy bruising, blood in stool, skin breakdown, fracture, poor wound healing, thin skin
Mobility (related to change in muscle and bone structure secondary to excess cortisol)Fatigue, muscle weakness, porous bones with fracture risk

Before the Study: Planning and Implementation

Teaching the Patient What to Expect

  • Inform the patient this test can assist in evaluating the amount of hormone produced by the pituitary gland located at the base of the brain.
  • Explain that a blood sample is needed for the test, samples are obtained at specific times to determine high and low levels of ACTH, and more than one sample may be necessary to ensure accurate results.
  • As appropriate, instruct the patient to report any postadministration reaction to metyrapone.

Potential Nursing Actions

  • Weigh patient and report weight to the pharmacy for accurate dosing of ordered metyrapone; may be 30 mg/kg body weight to a maximum of 3 grams total or per protocol.

After the Study: Potential Nursing Actions

Avoiding Complications

  • Observe/assess the patient who has been administered metyrapone for signs and symptoms of an acute adrenal (addisonian) crisis, which may include abdominal pain, anxiety, bone marrow depression, coma, confusion, decreased white blood cell count (WBC), dehydration, dizziness, sudden and significant fatigue or weakness, headache, hypotension, loss of consciousness, nausea and vomiting, excessively increased perspiration of the face and hands, shock, tachycardia, tachypnea. Potential interventions include immediate corticosteroid replacement (IV or IM), airway protection and maintenance, administration of dextrose for hypoglycemia, correction of electrolyte imbalance, and rehydration with IV fluids.

Treatment Considerations

  • Fluid volume: Monitor intake and output; assess for symptoms of fluid overload (shortness of breath, tachycardia, hypertension, positive jugular vein distention, edema). Monitor fluid and electrolytes for imbalance (potassium, sodium). Monitor heart rate, blood pressure, daily weight. Low-sodium diet. Administer prescribed medications (antihypertensive, diuretics).
  • Infection risk: Decrease environmental exposure by placing the patient in a private room or isolation, as appropriate; monitor and trend vital signs (heart rate, temperature, blood pressure) and laboratory values that would indicate an infection (WBC, CRP); promote good hygiene and assist as needed; administer prescribed medications (antibiotics, antipyretics) and IV fluids; use cooling measures; encourage oral fluids; obtain ordered cultures; encourage lightweight clothing and bedding.
  • Injury risk: Assess for bruising; assess stool for occult blood; assess for skin breakdown; assess wound for healing progress; facilitate ordered bone density screening.

Safety Considerations

  • Discuss adherence to the HCP's request to wear a medic alert bracelet indicating adrenal insufficiency and steroid use.
  • Mobility: Assist with activity; assist patient to meet activities of daily living; assess the severity of mobility limitations; implement the use of assistive devices as needed to prevent fall risk or injury.

Followup Evaluation and Desired Outcomes

  • Acknowledges contact information provided for the Cushing's Support and Research Foundation (https://csrf.net).
  • Understands that the results of this procedure may require additional testing to evaluate or monitor disease progression or necessary change in therapy. If a diagnosis of Cushing disease is made, pituitary computed tomography (CT) or magnetic resonance imaging (MRI) may be indicated prior to surgery. If a diagnosis of ectopic corticotropin syndrome is made, abdominal CT or MRI may be indicated prior to surgery.
  • Agrees to adhere to the HCP's request to increase oral fluid intake with a diet high in sodium and low in potassium (Addison disease).
  • Adheres to the prescribed administration of steroids and understands the necessity of altering the medication regime during times of illness and stress.

Adrenocorticotropic Hormone (and Challenge Tests) is a sample topic from the Davis's Lab & Diagnostic Tests.

To view other topics, please or purchase a subscription.

Nursing Central is the award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Learn more.

Citation

Bladh, Mickey Lynn., and Anne M. Van Leeuwen. "Adrenocorticotropic Hormone (and Challenge Tests)." Davis's Lab & Diagnostic Tests, 7th ed., F.A. Davis Company, 2017. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Lab-and-Diagnostic-Tests/425331/2/Adrenocorticotropic_Hormone__and_Challenge_Tests_.
Bladh ML, Van Leeuwen AM. Adrenocorticotropic Hormone (and Challenge Tests). Davis's Lab & Diagnostic Tests. 7th ed. F.A. Davis Company; 2017. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Lab-and-Diagnostic-Tests/425331/2/Adrenocorticotropic_Hormone__and_Challenge_Tests_. Accessed July 21, 2019.
Bladh, M. L., & Van Leeuwen, A. M. (2017). Adrenocorticotropic Hormone (and Challenge Tests). In Davis's Lab & Diagnostic Tests. Available from https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Lab-and-Diagnostic-Tests/425331/2/Adrenocorticotropic_Hormone__and_Challenge_Tests_
Bladh ML, Van Leeuwen AM. Adrenocorticotropic Hormone (and Challenge Tests) [Internet]. In: Davis's Lab & Diagnostic Tests. F.A. Davis Company; 2017. [cited 2019 July 21]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Lab-and-Diagnostic-Tests/425331/2/Adrenocorticotropic_Hormone__and_Challenge_Tests_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Adrenocorticotropic Hormone (and Challenge Tests) ID - 425331 A1 - Bladh,Mickey Lynn, AU - Van Leeuwen,Anne M, BT - Davis's Laboratory & Diagnostic Tests UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Lab-and-Diagnostic-Tests/425331/2/Adrenocorticotropic_Hormone__and_Challenge_Tests_ PB - F.A. Davis Company ET - 7 DB - Nursing Central DP - Unbound Medicine ER -